Log in

Endologix Stock Price, Forecast & Analysis (NASDAQ:ELGX)

$3.11
+0.11 (+3.67 %)
(As of 11/12/2019 08:55 AM ET)
Today's Range
$2.97
Now: $3.11
$3.13
50-Day Range
$2.32
MA: $3.41
$4.12
52-Week Range
$2.28
Now: $3.11
$11.30
Volume254,716 shs
Average Volume194,220 shs
Market Capitalization$55.79 million
P/E RatioN/A
Dividend YieldN/A
Beta0.26
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ELGX
CUSIP29266S10
Phone949-595-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$156.47 million
Book Value$3.83 per share

Profitability

Net Income$-79,710,000.00

Miscellaneous

Employees528
Market Cap$55.79 million
Next Earnings Date2/24/2020 (Estimated)
OptionableOptionable

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.


Endologix (NASDAQ:ELGX) Frequently Asked Questions

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

When did Endologix's stock split? How did Endologix's stock split work?

Shares of Endologix reverse split on Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of Endologix stock prior to the reverse split would have 10 shares after the split.

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) posted its earnings results on Wednesday, November, 6th. The medical instruments supplier reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.08. The medical instruments supplier had revenue of $35.78 million for the quarter, compared to analysts' expectations of $35.26 million. Endologix had a negative net margin of 58.24% and a negative return on equity of 99.62%. View Endologix's Earnings History.

When is Endologix's next earnings date?

Endologix is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Endologix.

What price target have analysts set for ELGX?

3 analysts have issued 12-month price objectives for Endologix's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Endologix's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 125.1% from the stock's current price. View Analyst Price Targets for Endologix.

What is the consensus analysts' recommendation for Endologix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endologix.

Has Endologix been receiving favorable news coverage?

Media coverage about ELGX stock has been trending very negative this week, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Endologix earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Endologix.

Are investors shorting Endologix?

Endologix saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,410,000 shares, an increase of 24.8% from the September 30th total of 1,130,000 shares. Based on an average trading volume of 214,700 shares, the days-to-cover ratio is presently 6.6 days. Currently, 9.5% of the shares of the company are sold short. View Endologix's Current Options Chain.

Who are some of Endologix's key competitors?

What other stocks do shareholders of Endologix own?

Who are Endologix's key executives?

Endologix's management team includes the folowing people:
  • Mr. John Onopchenko, CEO & Director (Age 60)
  • Mr. Vaseem Mahboob, Chief Financial Officer (Age 50)
  • Dr. Michael V. Chobotov, Chief Technology Officer (Age 58)
  • Mr. Jeffrey S. Brown, Chief Operations Officer
  • Mr. Jeremy B. Hayden, Gen. Counsel (Age 49)

Who are Endologix's major shareholders?

Endologix's stock is owned by many different of retail and institutional investors. Top institutional investors include Stephens Inc. AR (0.70%) and Russell Investments Group Ltd. (0.14%). Company insiders that own Endologix stock include Christopher G Chavez, Gregory D Waller, John Onopchenko, Thomas F Zenty III, Thomas Wilder and Vaseem Mahboob. View Institutional Ownership Trends for Endologix.

Which institutional investors are selling Endologix stock?

ELGX stock was sold by a variety of institutional investors in the last quarter, including Stephens Inc. AR. Company insiders that have sold Endologix company stock in the last year include Gregory D Waller and Thomas Wilder. View Insider Buying and Selling for Endologix.

Which institutional investors are buying Endologix stock?

ELGX stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. Company insiders that have bought Endologix stock in the last two years include John Onopchenko, Thomas F Zenty III and Vaseem Mahboob. View Insider Buying and Selling for Endologix.

How do I buy shares of Endologix?

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Endologix's stock price today?

One share of ELGX stock can currently be purchased for approximately $3.11.

How big of a company is Endologix?

Endologix has a market capitalization of $55.79 million and generates $156.47 million in revenue each year. The medical instruments supplier earns $-79,710,000.00 in net income (profit) each year or ($7.20) on an earnings per share basis. Endologix employs 528 workers across the globe.View Additional Information About Endologix.

What is Endologix's official website?

The official website for Endologix is http://www.endologix.com/.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]


MarketBeat Community Rating for Endologix (NASDAQ ELGX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  432 (Vote Outperform)
Underperform Votes:  429 (Vote Underperform)
Total Votes:  861
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe ELGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2019 by MarketBeat.com Staff

Featured Article: Oversold

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel